{"url_path":"/sec/cue/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1645460/0001193125-26-255479-index.html","accession_number":"0001193125-26-255479","cik":"0001645460","ticker":"CUE","issuer_name":"Cue Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645460/0001193125-26-255479-index.html","primary_entity_key":"0001645460","primary_entity_name":"Cue Biopharma, Inc."},"word_count":106,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits\n\n \n\n \n\nExhibit No.\n\nDescription\n\n10.1\n\n[Cue Biopharma, Inc. 2026 Stock Incentive Plan (incorporated by reference to Appendix A to the Company’s definitive proxy statement (File No. 001-38327) filed with the Securities and Exchange Commission on May 21, 2026)](https://www.sec.gov/Archives/edgar/data/0001645460/000119312526233369/d38874ddef14a.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\nCue Biopharma, Inc.\n\n \n\n \n\n \n\nDate: June 3, 2026\n\nBy:\n\n/s/ Shao-Lee Lin\n\n \n\nName:\n\nShao-Lee Lin\n\n \n\nTitle:\n\nPresident and Chief Executive Officer"}